Sethera Therapeutics’ Polymacrocyclic Peptide Platform Selected for CDMRP-Supported Mutant p53 Breast Cancer Program | Newswise - Newswise
Sethera Therapeutics’ Polymacrocyclic Peptide Platform Selected for CDMRP-Supported Mutant p53 Breast Cancer Program | Newswise Newswise
The science section covers breakthroughs in medicine, physics, biology, and technology. We surface discoveries that expand what humanity can do, from new treatments reaching clinical trials to engineering feats that seemed impossible a decade ago. Every link goes to the original publisher so you can read the full study or press release yourself.
BY THE OPTIMIST DAILY EDITORIAL TEAM New Mexico just became the first state to hold Meta financially liable for harms to…
BY THE OPTIMIST DAILY EDITORIAL TEAM There is something that makes adults uneasy about a child playing alone. A kid abso…
APOD Science APOD APOD: 2026 August 11 - Six… Today’s APOD Archive Submissions Index Search Calendar RSS Education About…
Earth Observatory Science Earth Observatory Bountiful Roebuck Bay Earth Earth Observatory Image of the Day EO Explorer T…